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ABSTRACT
Background: Previous reports suffer from the problem that they simply pooled data 
using aggregate means or standard meta‑analytic method. The aim of the current study 
was to re‑estimate the point prevalence of comorbid depression and anxiety in people 
with diabetes.
Methods: The estimates were calculated using recently introduced directly standardized 
effect estimate method, which gives corrected risk‑adjusted estimates for the population 
of interests. Reported are global and regional burden of prevalence, presented as 
risk‑adjusted prevalence estimates with 95% confidence intervals.
Results: Globally, the burden of comorbid depression was higher than the burden of 
anxiety (23.36% vs. 17.58%) symptoms and/or disorder in people with diabetes. There was 
a higher burden of comorbid depression in people living in developing regions (26.32%), in 
women (15.41%), and when assessed by self‑report scales (SRS) (22.66%). The burden of 
anxiety was higher in developed regions in people with Type 2 diabetes mellitus (20.15%) 
and when assessed by SRS (20.75%). No statistically significant differences were 
observed due to gross heterogeneity across countries.
Conclusions: There are wide‑ranging differences in studies in developed and developing 
regions, regarding the burden of comorbid depression and of anxiety among people with 
diabetes and both conditions affect approximately a fifth of the diabetic population.
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INTRODUCTION
Worldwide estimates of prevalence of depression and 
anxiety among people with diabetes seem to vary by 
diabetes type and where the study was conducted, 
including whether countries were developed or 
developing.[1-3] Depression and anxiety are two common 
mental health-related comorbidities in people with 
diabetes,[4] and their prevalence has been summarized 
in a number of systematic reviews.[5-8] A meta-analysis 
published in 2001 reported that 11% of the patients with 
diabetes had comorbid major depressive disorder and 
31% experienced significant depressive symptoms.[6] 
Another meta-analysis published in 2006 reported that 
the prevalence of clinical depression was significantly 
higher among patients with diabetes (17.6%) compared 
to those without diabetes (9.8%).[5]
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Both studies reported that the prevalence of depression 
in women with diabetes was double that of men with 
diabetes; they also estimated that the prevalence 
in people with diabetes was nearly twice that of 
people without diabetes.[5,6] The only meta-analysis 
on the prevalence of anxiety was published in 2002 by 
Grigsby et al., who reported that generalized anxiety 
disorder (GAD) was present in 14% of patients with 
diabetes; however, elevated symptoms of anxiety 
were found in 40% of the patients with diabetes who 
had participated in clinical studies.[7]
These previous reports suffer from the problem that 
they simply pooled data using aggregate means 
or standard meta-analytic methods,[5-8] which are 
inappropriate given that we are not seeking a common 
underlying estimate and therefore this approach could 
lead to biased prevalence estimates. What is actually 
more meaningful is a standardized rate, and the 
directly standardized rate is one of the most commonly 
used methods of standardization in epidemiologic 
studies,[9-11] but its use is limited to rates. Doi et al. 
recently introduced a directly standardized effect 
estimate (DSE) which can be used to standardize any 
effect size against the size of population at risk.[9] The 
aim of the current study was to re-estimate the point 
prevalence of comorbid depression and anxiety in 
people with diabetes using the DSE method which gives 
corrected risk-adjusted estimates for the population 
of interests.[9] We also stratified the estimates by the 
type of region (developed vs. developing), type of 
diabetes (Type 1 diabetes mellitus [T1DM] vs. T2DM), 
type of measurement (self-report vs. standard criteria), 
and gender (males vs. females).
METHODS
The databases PubMed, EMBASE, and PSYCINFO were 
systematically searched to identify relevant studies 
published between 2000 and 2014. The reason behind 
this search was to include more articles. Additional 
articles were sourced from the reference lists of relevant 
review articles and original research studies. Keywords 
included original terms, and synonyms related to 
diabetes, depression, and anxiety, and critical review 
were conducted by the principal investigator. The 
search strategy involved using the explode command 
with a search under the MeSH terms, for example, 
“depression/anxiety,” “depressive/anxiety disorder,” 
“major depressive disorder,” and “dysthymic disorder” 
combined with “diabetes mellitus” or “Type 2 diabetes 
mellitus.” This was supplemented with a keyword 
search of the terms “depression/anxiety,” “depressive/
anxiety disorder,” and “depressive/anxiety symptoms” 
combined using Boolean operators with “diabetes” and 
“diabetes mellitus.” We categorized the countries into 
developed and developing using the United Nations 
classification.[12] Developing world includes countries 
outside Europe, excluding Australia, Canada, Japan, 
New Zealand, the USA, Singapore, Hong Kong, 
and Taiwan.
Studies eligible for inclusion in this paper were 
required to assess T1DM and/or T2DM in an adult 
population with no limit on age. Studies were included 
only if they had a sample size ≥30, were published 
or available in English, and if a current estimate of 
proportion with depression or anxiety was available 
through self-reported diagnostic criteria. Included 
studies utilized both standard diagnostic criteria (SDC) 
as well as self-report scales (SRS) to measure these 
disorders and their symptoms. Standard criteria 
comprised structured or semi-structured interviews 
that were based on the Diagnostic and Statistical 
Manual of Mental Disorders. Elevated symptoms 
were assessed using self-report measures such as the 
Beck Depression Inventory or the hospital anxiety 
and depression scale.
Selection criteria were not restricted to studies 
comparing the occurrence of depression and/or 
anxiety disorders or elevated symptoms (using a 
clinically significant cutoff) in people with diabetes. 
Because there were many controlled studies that 
reported the prevalence of depression and anxiety in 
a nondiabetic group, prevalence in the latter studies 
was taken from the diabetic arm only. For studies that 
presented graded relationships such as low, medium, 
or high depressive symptoms, only the prevalence 
for the highest category was selected. Studies where 
the type of diabetes was not specified were included 
as T2DM because the ages of populations recruited 
suggested they would be predominantly subjects 
with T2DM.
The quality of the included studies was rated 
independently by the authors using criteria that 
include adequacy of the description of groups (T1DM 
and T2DM, diabetes mellitus, T1DM and T2DM 
with depression/anxiety, control without 
depression/anxiety, and control with depression/
anxiety), control for confounding variables, and 
representativeness of sampling.
Statistical analysis
Each study was examined for information regarding 
the events of comorbid depression and anxiety in 
Hasan, et al.: Burden of comorbid depression and anxiety in people with diabetes
82 Archives of Pharmacy Practice  Vol. 7  Issue 3  Jul‑Sep 2016
people with diabetes. For studies that reported events 
separately by gender (males vs. females), type of 
assessment (SRS vs. SDC), and type of diabetes 
(T1DM vs. T2DM), events were extracted and burden 
of depression and anxiety within these subgroups 
were calculated.
In addition to comorbid depression and anxiety 
disorders, data on depression and anxiety symptoms as 
well as specific anxiety disorders were extracted (GAD, 
panic disorder, phobias, and post-traumatic stress 
disorder).
The country-specific prevalence of comorbid 
depression and anxiety was then used to pool 
the burden of these disorders in specific broad 
populations using the DSE approach.[9] This process 
involves adjustment for different sizes of populations 
at risk when computing summary measures across 
populations with diabetes. The population size at risk 
was the prevalence of diabetes across the different 
countries in the world obtained from the International 
Diabetes Federation.[13] Sensitivity analysis was also 
conducted by publication years to explore potential 
heterogeneity.
This approach is similar to direct standardization 
using the diabetes subpopulation size to adjust 
prevalence estimates such that larger populations 
contribute more to the pooled estimate for a region 
than smaller populations.[9] Thus, the DSE is a type of 
direct standardization and can be calculated as:
( )aj j
a
j
× ES
DSE =
w
w
∑
∑
where the weight is defined as described by Doi 
et al. and j indexes the subpopulations and ESj is the 
subpopulation effect estimate of interest (the double 
arcsine square root transformed proportion in 
this study with results back transformed for 
reporting).[9] This weighted averaging procedure 
does not use inverse variance weights and thus is 
not a meta-analysis.[9] For countries where more 
than one study was available, a single estimate 
was obtained through standard meta-analysis, thus 
ensuring that each country provided a single estimate. 
This meta-analysis (within country) was conducted 
using an inverse variance quasi likelihood-based 
alternative (IVhet) to the random effects model.[14] 
Data were analyzed using Stata 12 (StataCorp LP, 
TX, USA), MetaXL 2.0 (EpiGear International Pty Ltd, 
Queensland, Australia) and Microsoft Excel. Linear 
regression analysis was used to examine the trend of 
prevalence between 2000 and 2013.
RESULTS
The 103 studies selected for review generated 
103 data sets, of which 71 examined the prevalence 
of depression in people with diabetes and 32 examined 
the prevalence of anxiety in people with diabetes. Of 
the 71 studies assessing the prevalence of depression in 
people with diabetes, 37 studies were from developed 
and 34 from developing countries. Similarly, to 
estimate the prevalence of anxiety in people with 
diabetes, a comprehensive review was conducted 
on 17 studies from developed and 15 studies from 
developing countries, as shown in Figure 1.
Burden of depression
Global
The burden of comorbid depression symptoms and/or 
disorder in people with diabetes was 23.36%, which 
was similar to the burden of symptoms only at 24.50% 
and the burden of any depressive disorder at 22.27% 
[Table 1].
Developed
The burden of comorbid depression in T1DM and 
T2DM was similar (13.47 vs. 17.9%). Subgroups 
by SDC (21.70%) or female gender (12.92%) made 
up a greater burden than self-reports and males, 
respectively [Table 1]. The sensitivity analysis by 
3223 articles were identified. Titles of 
each article were screened to identify.
potentially relevant articles (n = 216)
Abstract were examined and excluded if 
studies involved were published prior to
 January, 2000 and if sample size <30;
n = 95
Articles retrieved for more detailed 
evaluation of the full text (n = 121)
Articles excluded after full text evaluation 
(n = 18): no prevalence data and 
inadequate information
Relevant articles included in this
 paper (n = 103)
Datasets included in analyses (n = 103)
71 = Articles examining prevale
nce of depression
32 = Articles examining prevalence
of anxiety
Figure 1: Flow diagram of study selection process
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publication years presented a declining trend in 
the prevalence of depression where prevalence was 
lowest in the recent years (2010 onward) [Figure 2].
Developing
Trends were similar to developed nations except 
that self-reports demonstrated exaggerated estimates 
of burden [Table 1]. The prevalence was higher in 
the recent years (2010 onward) compared to the 
prevalence between 2000 and 2009.
Burden of anxiety
Global
The burden of comorbid anxiety symptoms or 
disorder in people with diabetes was lower than that 
of depression (17.58%), the burden of symptoms was 
20.16%, and the burden of any anxiety disorder was 
7.11% [Table 1].
Developed
The burden of comorbid anxiety in people with T1DM 
(17.00%) was similar to T2DM (20.15%) [Table 1]. 
Again, subgroups by female gender and self-reports 
made up a higher burden than male gender and 
standard criteria, respectively [Table 1]. The prevalence 
was highest between 2005 and 2009, and almost same 
in other two groups (2000–2004 and 2010–2014).
Developing
Again, self-reports were associated with a much 
higher burden of anxiety than standard criteria. The 
sensitivity analysis by publication years showed 
an increasing trend in the prevalence of anxiety 
where prevalence was highest in the years between 
2010 and 2014 [Figure 2].
DISCUSSION
Our findings suggest that about one in eight people 
with diabetes living in developed regions and one in 
four people with diabetes living in developing region 
are likely to experience depression symptoms. We 
also notice that depression and anxiety demonstrate 
a greater burden in females with diabetes and by 
self-reports. The burden of depression in people 
with diabetes tended to be lower in developed 
regions compared to developing regions. However, 
a reverse trend was seen for anxiety, being higher 
in developed regions than developing regions, in 
people with T2DM. Baxter et al. also suggested that 
Table 1: The standardized prevalence estimates of comorbid depression and anxiety in people with diabetes 
by developed and developing countries
Region Variable Prevalence of depression (%) Prevalence of anxiety (%)
ES 95% CI ES 95% CI
LCI UCI LCI UCI
Global Symptoms or disorder 23.36 5.03 49.72 17.58 4.22 37.44
Symptoms 24.50 5.27 51.86 20.16 5.17 41.68
Any disorder 22.27 3.13 51.98 7.11 1.04 17.87
Developed T2DM + T1DM 13.58 1.61 32.37 15.46 2.63 36.17
T2DM 13.47 1.10 36.42 20.15 8.57 35.09
T1DM 17.90 1.00 51.33 17.00 1.00 42.80
Self‑report 14.53 3.27 30.85 22.26 4.49 48.39
Standard criteria 21.70 3.20 66.20 11.72 2.60 25.23
Male 6.55 2.94 24.94 17.50 1.60 42.20
Female 12.92 1.00 38.68 23.30 14.90 32.90
Developing T2DM 26.32 1.00 64.93 18.19 2.15 44.90
Self‑report 30.79 9.64 57.51 19.24 2.72 45.71
Standard criteria 2.20 2.00 52.20 2.50 0.70 5.10
Male 10.30 0.20 28.80 8.27 1.27 41.16
Female 17.90 4.70 36.30 15.21 1.20 50.99
DSE=Directly standardized effect estimate, T1DM=Type 1 diabetes mellitus, CI=Confidence interval, LCI=Lower confidence interval, UCI=Upper confidence interval, 
ES=Effect size, T2DM=Type 2 diabetes mellitus
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anxiety was more common in general population 
living in high-income regions compared to low- or 
middle-income regions.[15]
Unlike the previous reviews,[5-7] one of the strengths 
of this study is the use of standardized prevalence 
estimates. Previous estimates seem to have been biased 
upward and for instance, the reported 40% prevalence 
of comorbid anxiety in people with diabetes[7] was 
revised downward to 20% in this study [Table 2].
This study was based on SRS and thus, their validity 
is of paramount importance. This does not seem to 
pose a problem because these scales used for screening 
for depression and anxiety have been shown to be 
reliable and valid,[16] and are often employed in 
epidemiological surveys such as those investigated 
in this study. However, the diagnosis of diabetes 
is also important and again it has been shown in a 
meta-analysis that the prevalence of depression varies 
little across assessments by blood glucose measures, 
physician diagnosis, or patient self-report.[17]
Regarding gender, our findings suggest that about 
one in eight females with diabetes living in developed 
region and one in six females with diabetes living in 
developing region are likely to report depression. This 
is consistent with the reports from earlier studies.[5,6] 
Similarly, the prevalence of gender difference between 
females and males has been previously reported.[7] 
Even in the general population, women are more 
likely to experience mood disorders compared to 
men,[18] so this is not unexpected.
The overall burden of any anxiety disorder in people 
with diabetes was within the range of 12–21% as 
reported for the general population.[19-21] Depression 
was however found to be higher (23%) compared to 
the general population (10%).[5] Finally, the prevalence 
of the GAD found in developed regions is comparable 
to the 3–4% observed in community studies in the 
United States.[22,23] Since this burden is within or close 
to the range of estimates reported for the general 
population, there is a possibility that the burden can 
be explained by factors other than diabetes per se that 
share a relationship with both diabetes and depression 
or anxiety. For instance, obesity has been shown to be 
associated with the former condition as well as with 
diabetes.[24,25]
Comorbid depression and anxiety disorders and 
elevated symptoms in people with diabetes have 
been shown to be associated with increased diabetes 
complications,[1] worsened blood glucose levels,[26,27] 
and reduced quality of life.[28] This is of particular 
concern to developing regions where resources to 
address depression and anxiety are not adequate.[29] 
Indeed, it has been reported that about 35–50% of 
serious cases in developed countries and about 76% to 
85% in less-developed countries received no treatment 
in the 12 months preceding the interview.[30]
There were a limited number of studies using standard 
criteria to diagnose depression and anxiety disorders. 
It is possible that some estimates and confidence 
intervals may be unstable because of the small number 
of subjects used in the calculations, and there is a 
concern about variability in the methods used to 
identify cases of depression and anxiety. Various 
SRSs were used to measure depression and anxiety 
symptoms, and even in studies that employed the 
same scales, different threshold scores were used.
We had samples from a variety of settings including 
primary, secondary, and community settings. Patients 
with diabetes recruited from a secondary-care 
setting are likely to differ from those selected from 
primary-care and population settings with regard to 
Table 2: Comparison of comorbid depression and anxiety in people with diabetes in percentage reported by 
different studies
Variables Global 
burden (risk 
adjustment)
Burden in 
developed 
regions risk 
adjustment)
Burden in 
developing 
regions (risk 
adjustment)
Gavard 
et al., 1993 ‑ 
Burden 
(proportion)
Anderson 
et al., 2001 ‑ 
Burden 
(aggregate 
mean)
Grigsby 
et al., 2002 
‑ Burden 
(aggregate 
mean)
Ali 
et al., 2006 ‑ 
Burden 
(meta‑analysis)
Depressive symptoms 24.50 14.53 30.79 26.0 31.0 ‑ 17.60
Any depressive disorder 22.27 21.70 2.20 ‑ ‑ ‑
Anxiety symptoms 20.16 22.26 19.24 ‑ ‑ 39.60 ‑
Any anxiety disorder 7.11 11.72 2.50 ‑ ‑ 14.00 ‑
GAD 8.76 5.41 12.10 ‑ ‑ 13.50 ‑
PTSD 2.30 3.10 1.50 ‑ ‑ 1.20 ‑
Any phobia 9.82 13.27 6.37 ‑ ‑ 10.10 ‑
GAD=Generalized anxiety disorder, PTSD=Post‑traumatic stress disorder
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disease stage and severity.[31] No statistically significant 
differences were seen due to gross heterogeneity 
across countries. Despite these limitations, this review 
presents significant findings regarding standardized 
prevalence of comorbid mental health conditions 
in people with diabetes living in different types of 
countries.
The association between depression and diabetes and 
anxiety and diabetes may have deleterious impact 
on public and individual health. Once depression 
or anxiety develops, it can represent a barrier to 
glycemic control.[32] Unfortunately, both conditions 
often remain unrecognized and thus untreated.[33] The 
burden of depression found in this study is higher 
in people with diabetes than in general population. 
However, the burden of anxiety seems to be similar in 
diabetes as in the general population. The burden of 
comorbid depression and anxiety tended to be higher 
in people with diabetes living in developing region 
compared to developed region, and in females relative 
to males with diabetes. The above findings that people 
with diabetes are at a higher risk of having depression 
and anxiety should alert clinicians to screen and treat 
anxiety and depression in people with diabetes.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
REFERENCES
1. Collins MM, Corcoran P, Perry IJ. Anxiety and depression 
symptoms in patients with diabetes. Diabet Med 
2009;26:153‑61.
2. Egede LE, Zheng D, Simpson K. Comorbid depression 
is associated with increased health care use and 
expenditures in individuals with diabetes. Diabetes Care 
2002;25:464‑70.
3. Katon W, Russo J, Lin EH, Heckbert SR, Ciechanowski P, 
Ludman EJ, et al. Depression and diabetes: Factors 
associated with major depression at five‑year follow‑up. 
Psychosomatics 2009;50:570‑9.
4. Smith KJ, Béland M, Clyde M, Gariépy G, Pagé V, 
Badawi G, et al. Association of diabetes with anxiety: A 
systematic review and meta‑analysis. J Psychosom Res 
2013;74:89‑99.
5. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The 
prevalence of co‑morbid depression in adults with type 2 
diabetes: A systematic review and meta‑analysis. Diabet 
Med 2006;23:1165‑73.
6. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. 
The prevalence of comorbid depression in adults with 
diabetes: A meta‑analysis. Diabetes Care 2001;24:1069‑78.
7. Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, 
Lustman PJ. Prevalence of anxiety in adults with diabetes: 
A systematic review. J Psychosom Res 2002;53:1053‑60.
8. Mirza I, Jenkins R. Risk factors, prevalence, and treatment 
of anxiety and depressive disorders in Pakistan: 
Systematic review. BMJ 2004;328:794.
9. Doi SA, Barendregt JJ, Rao C. An updated method for 
risk adjustment in outcomes research. Value Health 
2014;17:629‑33.
10. Armitage P, Berry G. Statistical Methods in Medical 
Research. 3rd ed. Oxford: Blackwell; 1994.
11. Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence 
intervals for weighted sums of poisson parameters. Stat 
Med 1991;10:457‑62.
12. United Nations, Population Division. World Population 
Prospects: The 2006 Revision. Geneva: United Nations; 2007.
13. International Diabetes Federation Altas (IDF). 6th ed. 
Available from: http://www.idf.org/diabetesatlas. 
[Last accessed on 2014 Sep 15].
14. MetaXL, EpiGear International Pty Ltd. Available from: 
http://www.epigear.com/index_files/MetaXL%20User%20
Guide.pdf. [Last accessed on 2014 Sep 15].
15. Baxter AJ, Vos T, Scott KM, Norman RE, Flaxman AD, 
Blore J, et al. The regional distribution of anxiety 
disorders: Implications for the global burden of disease 
study, 2010. Int J Methods Psychiatr Res 2014;23:422‑38.
16. Roy T, Lloyd CE, Pouwer F, Holt RI, Sartorius N. Screening 
tools used for measuring depression among people with 
type 1 and type 2 diabetes: A systematic review. Diabet 
Med 2012;29:164‑75.
17. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, 
Pouwer F. Depression as a risk factor for the onset of 
type 2 diabetes mellitus. A meta‑analysis. Diabetologia 
2006;49:837‑45.
18. Kessler RC, Chiu WT, Demler O, Merikangas KR, 
Walters EE. Prevalence, severity, and comorbidity of 
12‑month DSM‑IV disorders in the National Comorbidity 
Survey Replication. Arch Gen Psychiatry 2005;62:617‑27.
19. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, 
Walters EE. Lifetime prevalence and age‑of‑onset 
distributions of DSM‑IV disorders in the National 
Comorbidity Survey Replication. Arch Gen Psychiatry 
2005;62:593‑602.
20. Leray E, Camara A, Drapier D, Riou F, Bougeant N, 
Pelissolo A, et al. Prevalence, characteristics and 
comorbidities of anxiety disorders in France: Results 
from the “Mental Health in General Population” survey 
(MHGP). Eur Psychiatry 2011;26:339‑45.
21. McEvoy PM, Grove R, Slade T. Epidemiology of anxiety 
disorders in the Australian general population: Findings 
Hasan, et al.: Burden of comorbid depression and anxiety in people with diabetes
86 Archives of Pharmacy Practice  Vol. 7  Issue 3  Jul‑Sep 2016
of the 2007 Australian National Survey of Mental Health 
and Wellbeing. Aust N Z J Psychiatry 2011;45:957‑67.
22. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM‑III‑R 
generalized anxiety disorder in the National Comorbidity 
Survey. Arch Gen Psychiatry 1994;51:355‑64.
23. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, 
Eshleman S, et al. Lifetime and 12‑month prevalence of 
DSM‑III‑R psychiatric disorders in the United States. 
Results from the National Comorbidity Survey. Arch Gen 
Psychiatry 1994;51:8‑19.
24. Atlantis E, Baker M. Obesity effects on depression: 
Systematic review of epidemiological studies. Int J Obes 
(Lond) 2008;32:881‑91.
25. Gariepy G, Nitka D, Schmitz N. The association between 
obesity and anxiety disorders in the population: A 
systematic review and meta‑analysis. Int J Obes (Lond) 
2010;34:407‑19.
26. Anderson RJ, Grigsby AB, Freedland KE, de Groot M, 
McGill JB, Clouse RE, et al. Anxiety and poor glycemic 
control: A meta‑analytic review of the literature. Int J 
Psychiatry Med 2002;32:235‑47.
27. Shaban C, Fosbury JA, Cavan DA, Kerr D, Skinner TC. 
The relationship between generic and diabetes specific 
psychological factors and glycaemic control in adults with 
type 1 diabetes. Diabetes Res Clin Pract 2009;85:e26‑9.
28. Schram MT, Baan CA, Pouwer F. Depression and quality of 
life in patients with diabetes: A systematic review from 
the European depression in diabetes (EDID) research 
consortium. Curr Diabetes Rev 2009;5:112‑9.
29. Stein DJ, Gureje O. Depression and anxiety in the 
developing world: Is it time to medicalise the suffering? 
Lancet 2004;364:233‑4.
30. Demyttenaere K, Bruffaerts R, Posada‑Villa J, Gasquet I, 
Kovess V, Lepine JP, et al. Prevalence, severity, and unmet 
need for treatment of mental disorders in the World 
Health Organization World Mental Health Surveys. JAMA 
2004;291:2581‑90.
31. Wilson S, Delaney BC, Roalfe A, Roberts L, Redman V, 
Wearn AM, et al. Randomised controlled trials in primary 
care: Case study. BMJ 2000;321:24‑7.
32. Silva N, Atlantis E, Ismail K. A review of the association 
between depression and insulin resistance: Pitfalls of 
secondary analyses or a promising new approach to 
prevention of type 2 diabetes? Curr Psychiatry Rep 
2012;14:8‑14.
33. Pouwer F. Should we screen for emotional distress 
in type 2 diabetes mellitus? Nat Rev Endocrinol 
2009;5:665‑71.
